Bibliography
- Kantoff PW, Higano CS, Shore ND, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
- Madan RA, Arlen PM, Mohebtash M, Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009;18:1001-11
- Kantoff PW, Schuetz TJ, Blumenstein BA, Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105
- Stein WD, Gulley JL, Schlom J, Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011;17:907-17
- SEER Cancer Statistics Review 1975 – 2009 (Vintage 2009 Populations). Available from: http://seer.cancer.gov/csr/1975_2009_pops09/ [Cited September 2012]
- American Cancer Society: Cancer Facts & Figures. 2012. Available from: http://www.cancer.org/Research/CancerFactsFigures/index [Cited September 2012]
- Yervoy* ipilimumab product monograph. 2012. Available from: http://www.bmscanada.ca/static/products/en/pm_pdf/Yervoy_EN_PM.pdf
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64
- Topalian SL, Hodi FS, Brahmer JR, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
- Brahmer JR, Tykodi SS, Chow LQ, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
- Woo SR, Turnis ME, Goldberg MV, Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72:917-27
- Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010;11:7-13
- Brunkow ME, Jeffery EW, Hjerrild KA, Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001;27:68-73
- Wahl SM, Orenstein JM, Chen W. TGF-beta influences the life and death decisions of T lymphocytes. Cytokine Growth Factor Rev 2000;11:71-9
- Fehervari Z, Yamaguchi T, Sakaguchi S. The dichotomous role of IL-2: tolerance versus immunity. Trends Immunol 2006;27:109-11
- Tivol EA, Borriello F, Schweitzer AN, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7
- Collins AV, Brodie DW, Gilbert RJ, The interaction properties of costimulatory molecules revisited. Immunity 2002;17:201-10
- Walunas TL, Lenschow DJ, Bakker CY, CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13
- Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002;16:23-35
- Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011;11:852-63
- Waterhouse P, Penninger JM, Timms E, Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985-8
- Chambers CA, Cado D, Truong T, Allison JP. Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci USA 1997;94:9296-301
- Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6
- Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302
- Wing K, Yamaguchi T, Sakaguchi S. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol 2011;32:428-33
- Metzler B, Burkhart C, Wraith DC. Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo. Int Immunol 1999;11:667-75
- Wing K, Onishi Y, Prieto-Martin P, CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322:271-5
- Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935-45
- Kavanagh B, O'Brien S, Lee D, CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008;112:1175-83
- Read S, Greenwald R, Izcue A, Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006;177:4376-83
- Zeh HJ III, Perry-Lalley D, Dudley ME, High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-94
- Bullock TN, Mullins DW, Colella TA, Engelhard VH. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J Immunol 2001;167:5824-31
- Hodge JW, Chakraborty M, Kudo-Saito C, Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005;174:5994-6004
- Kwon ED, Hurwitz AA, Foster BA, Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997;94:8099-103
- Pilon SA, Kelly C, Wei WZ. Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J Immunol 2003;170:1202-8
- Chakraborty M, Abrams SI, Coleman CN, External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64:4328-37
- Demaria S, Kawashima N, Yang AM, Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11:728-34
- Waitz R, Solomon SB, Petre EN, Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 2012;72:430-9
- Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998;95:10067-71
- van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-66
- Hurwitz AA, Foster BA, Kwon ED, Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60:2444-8
- Garnett C, Farsaci B, Schlom J, Hodge JW. Docetaxel modulates phenotype of human carcinoma cells, including drug-resistant tumor cells, resulting in enhanced killing by CTLs [abstract 4790]. Proceedings: 101st AACR Annual Meeting; 2010
- Hodge JW, Ardiani A, Farsaci B, The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 2012;39:323-39
- Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957-71
- Mercader M, Bodner BK, Moser MT, T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001;98:14565-70
- Gannon PO, Poisson AO, Delvoye N, Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009;348:9-17
- Drake CG, Doody AD, Mihalyo MA, Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239-49
- Sutherland JS, Goldberg GL, Hammett MV, Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005;175:2741-53
- Roden AC, Moser MT, Tri SD, Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004;173:6098-108
- Page ST, Plymate SR, Bremner WJ, Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab 2006;290:E856-63
- Lechleider RJ, Arlen PM, Tsang KY, Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008;14:5284-91
- Gulley JL, Arlen PM, Bastian A, Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62
- Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7
- Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480(7378):480-9
- Small EJ, Tchekmedyian NS, Rini BI, A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13:1810-15
- Study of Immunotherapy to Treat Advanced Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00861614?term=NCT00861614&rank=1 [Cited September 2012]
- Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01057810?term=NCT01057810&rank=1 [Cited September 2012]
- Slovin S, Hamid O, Tejwani S, Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): results from an open-label, multicenter phase I/II study. J Clin Oncol 2012;30(5S):abstract 25
- Small EJ, Higano CS, Tchekmedyian NS, Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. J Clin Oncol 2006;24(18S):abstract 4609
- Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
- Tollefson M, Kames R, Thompson R, A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer [poster] [abstract 168]. ASCO Genitourinary Cancers Symposium; 2010
- McNeel DG, Smith HA, Eickhoff JC, Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother 2012;61:1137-47
- Harzstark A, Fong L, Weinberg V, Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2010;28(15S):abstract 4689
- van den Eertwegh AJ, Versluis J, van den Berg HP, Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:509-17
- Madan RA, Mohebtash M, Arlen PM, Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:501-8
- Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010;15(9):969-75
- Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011;17(12):3884-91
- Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011;8(9):551-61
- Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13:3776-82
- Scher HI, Halabi S, Tannock I, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-59
- Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012;33:35-41
- Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol 2001;22:564-71
- Sportes C, Babb RR, Krumlauf MC, Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010;16:727-35
- Burchill MA, Yang J, Vang KB, Farrar MA. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett 2007;114:1-8
- Borrello IM, Levitsky HI, Stock W, Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009;114:1736-45
- Greiner JW, Guadagni F, Noguchi P, Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 1987;235:895-8
- Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012;104:599-613
- Litzinger MT, Fernando R, Curiel TJ, IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007;110:3192-201
- Morris J, Shapiro G, Tan A, Phase I/II study of GC1008: a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 2008;26(Suppl):abstract 9028
- Schaer DA, Cohen AD, Wolchok JD. Anti-GITR antibodies–potential clinical applications for tumor immunotherapy. Curr Opin Investig Drugs 2010;11:1378-86
- Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Science gone translational: the OX40 agonist story. Immunol Rev 2011;244:218-31
- Lynch DH. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 2008;222:277-86
- Morgan RA, Dudley ME, Wunderlich JR, Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9
- Urba WJ, Longo DL. Redirecting T cells. N Engl J Med 2011;365:754-7
- Ruggeri L, Mancusi A, Capanni M, Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005;17:211-17
- Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01510288 [Cited September 2012]
- Phase I Trial of a PSA Based Vaccine and an Anti-CTLA-4 Antibody in Adults With Metastatic Androgen Independent Prostrate Cancer. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00113984?term=NCT00113984&rank=1 [Cited September 2012]
- Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00064129?term=NCT00064129&rank=1 [Cited September 2012]
- Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00050596?term=NCT00050596&rank=1 [Cited September 2012]
- MDX-010 for Advanced Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00170157?term=NCT00170157&rank=1 [Cited September 2012]
- Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01377389?term=NCT01377389&rank=1 [Cited September 2012]
- Neoadjuvant Ipilimumab in Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01194271?term=NCT01194271&rank=1 [Cited September 2012]
- Ipilimumab and GMCSF Immunotherapy for Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01530984?term=NCT01530984&rank=1 [Cited September 2012]
- Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01498978?term=NCT01498978&rank=1 [Cited September 2012]
- Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (MDX010-21). Available from: http://clinicaltrials.gov/ct2/show/NCT00323882?term=NCT00323882&rank=1 [Cited September 2012]
- Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naive Patients With Progressive Metastatic Castration-resistant Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01688492?term=NCT01688492&rank=1 [Cited September 2012]
- Robert C, Thomas L, Bondarenko I, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26